After the discontinuation of protease inhibitors, our data suggested a decreasing trend in triglyceride levels, even after the initiation of TAF.
← all excerpts
Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis.
1
—
—